证券代码：688131 证券简称：皓元医药 公告编号：2023-049 上海皓元医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海皓元医药股份有限公司（以下简称"公司"）于 2023 年 3 月 22 日、4 月 28 日分别在上海证券交易所网站（www.sse.com.cn）发布公司 2022 年年度报告 及 2023 年第一季度报告。为便于广大投资者更全面深入地了解公司 2022 年年度 及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 16 日下午 13:00-14:30 举行 2022 年度暨 2023 年第一季度业绩暨现金分红说明会，就投资 者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频直播结合网络互动召开，公司将针对 2022 年年度 及 2023 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流和沟 1 会议召开时间：2023 年 5 月 16 ...

Financial Performance - The company's total revenue for Q1 2023 reached RMB 418.37 million, representing a year-on-year increase of 39.46%[6] - The net profit attributable to shareholders decreased by 25.83% to RMB 46.24 million, while the net profit after deducting non-recurring gains and losses fell by 28.64% to RMB 41.96 million[6] - Total operating costs for Q1 2023 were ¥354,607,032.39, up 61.1% from ¥219,865,620.60 in Q1 2022[25] - Net profit for Q1 2023 was ¥46,068,348.53, a decrease of 25.5% from ¥61,771,891.90 in Q1 2022[26] - Operating profit for Q1 2023 was ¥47,936,796.00, down 29.3% from ¥67,898,249.96 in Q1 2022[25] - Basic earnings per share for Q1 2023 were ¥0.43, compared to ¥0.60 in Q1 2022[26] Research and Development - Research and development expenses totaled RMB 50.52 million, an increase of 50.95% year-on-year, accounting for 12.08% of total revenue[6] - Research and development expenses for Q1 2023 were ¥50,524,023.51, an increase of 50.9% from ¥33,470,762.57 in Q1 2022[25] - The company is actively enhancing its R&D capabilities with centers in multiple cities and is expanding its business operations internationally[12] - The company continues to focus on innovation and has implemented stock incentive plans for over 300 employees to support its strategic goals[13] - The company is focusing on technological innovation and industrial upgrades as part of its strategic initiatives[16] Assets and Liabilities - The company's total assets increased by 5.53% to RMB 3.80 billion compared to the end of the previous year[8] - The total current assets as of March 31, 2023, amounted to CNY 1,897,890,597.80, an increase from CNY 1,822,869,836.48 at the end of 2022, reflecting a growth of approximately 4.0%[19] - The total non-current assets as of March 31, 2023, were CNY 123,084,820.60, slightly up from CNY 75,590,454.31 at the end of 2022[19] - Total liabilities amounted to ¥1,408,819,244.19, up 11.3% from ¥1,265,778,968.40 in Q1 2022[21] Cash Flow - The company reported a significant increase in cash outflows from operating activities, primarily due to increased inventory purchases and higher employee compensation costs[11] - The net cash flow from operating activities was CNY -147,839,554.95, compared to CNY -3,784,513.39 in the same period last year[28] - The total cash outflow from operating activities was CNY 521,737,913.70, compared to CNY 262,392,414.67 in Q1 2022[28] - The total cash inflow from operating activities was CNY 373,898,358.75, an increase from CNY 258,607,901.28 in the same quarter last year[28] - The cash inflow from investment activities was CNY 341,445,562.65, significantly higher than CNY 47,474,574.57 in Q1 2022[29] - The cash inflow from financing activities was CNY 193,321,701.42, up from CNY 112,400,000.00 in Q1 2022[29] Shareholder Information - The top shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 32.47% of the company's shares, totaling 34,736,166 shares[15] - The company reported a total of 7,674,660 shares held by the top shareholder, representing a significant portion of the total shares outstanding[16] - The company has a total of 1,989,724 shares held by China Industrial Bank, indicating strong institutional support[17] Workforce - The company expanded its workforce to 3,581 employees, an increase of 213 employees compared to the end of the previous year, primarily in production and technical roles[13] Other Information - The company has not reported any significant mergers or acquisitions during the quarter[18] - There are no significant changes in the company's financing or margin trading activities reported for this period[18] - Cash and cash equivalents decreased to CNY 304,569,982.51 from CNY 460,137,636.91, representing a decline of about 33.7%[19] - Inventory increased significantly to CNY 1,070,725,002.15, up from CNY 910,876,848.98, indicating a rise of approximately 17.6%[19] - Accounts receivable rose to CNY 407,502,261.10 from CNY 336,860,225.55, marking an increase of around 20.9%[19] - The ending balance of cash and cash equivalents was CNY 300,142,110.84, down from CNY 853,568,279.69 at the end of Q1 2022[29]

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 193,643,498.25 in 2022, with the parent company reporting a net profit of RMB 91,366,221.47[8]. - The company reported a significant increase in revenue, with a year-over-year growth of 25% in 2022[16]. - The company's operating revenue for 2022 was ¥1,358,053,975.22, representing a 40.12% increase compared to ¥969,225,559.54 in 2021[29]. - The net profit attributable to shareholders for 2022 was ¥193,643,498.25, a slight increase of 1.39% from ¥190,979,580.89 in 2021[29]. - The net cash flow from operating activities decreased significantly to -¥240,232,931.24, down 515.38% from ¥57,834,553.22 in 2021[29]. - The total assets at the end of 2022 reached ¥3,597,744,539.58, a 50.88% increase from ¥2,384,551,589.19 at the end of 2021[29]. - The company's net assets attributable to shareholders increased by 27.31% to ¥2,319,917,990.08 at the end of 2022, compared to ¥1,822,307,191.98 at the end of 2021[29]. - The basic earnings per share for 2022 was ¥1.86, a decrease of 11.43% from ¥2.10 in 2021[30]. - The company's gross profit margin was affected by rising operating costs, with operating costs increasing by 48.28% to CNY 659,411,057.33[168]. Dividend and Share Capital - The proposed cash dividend is RMB 3.80 per 10 shares, totaling RMB 40,653,263.36, which represents 20.99% of the annual net profit attributable to shareholders[8]. - The company plans to increase its total share capital by 42,792,908 shares through a capital reserve transfer, raising the total share capital to 149,775,180 shares[8]. - The company has a total of 106,982,272 shares as of March 20, 2023, which serves as the basis for dividend distribution and capital increase calculations[8]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new drug development initiatives[18]. - The R&D expenditure as a percentage of operating revenue increased to 14.84% in 2022, up 4.17 percentage points from 10.67% in 2021[30]. - R&D investment reached 201.58 million yuan, a 94.85% increase compared to the previous year, accounting for 14.84% of total revenue[62]. - The company has developed over 5,900 types of recombinant proteins and antibodies, providing high-quality biological research reagents and technical services to global pharmaceutical R&D enterprises and life science research institutions[50]. - The company has developed a comprehensive service platform covering drug research and production, with approximately 7,000 global partners[68]. Market Expansion and Strategy - The company provided a positive outlook for 2023, projecting a revenue growth of 20%[18]. - Market expansion plans include entering three new international markets by the end of 2023[16]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal valued at approximately $100 million[17]. - The company aims to increase its market share by 5% through enhanced marketing strategies and customer engagement[16]. - The company is focused on the strategic transformation of its generic drug CDMO business towards innovative drugs to create higher value[80]. Risk Management - The company has outlined various risks in its operations and has provided measures to mitigate these risks, as detailed in the management discussion and analysis section[6]. - The company has confirmed that there are no violations in decision-making procedures for external guarantees[12]. - The company faces risks related to talent retention and potential core technology leakage due to rapid business expansion and increased competition[153]. - The company has adopted a systematic approach to risk management, including strict inventory impairment policies to mitigate financial risks[159]. Acquisitions and Partnerships - The company acquired 100% equity of Yaoyuan Pharmaceutical, contributing to the increase in total assets[33]. - The company completed the acquisition of 100% equity in Yaoyuan Pharmaceutical, enhancing its formulation CDMO capabilities and expanding GMP production capacity[57]. - The company has established a new strategic partnership with a leading CRO to accelerate drug development timelines[18]. - The company acquired 100% equity of Zeda Fan Ke and Ya Yuan Pharmaceutical, enhancing its CDMO service capabilities[44]. Operational Efficiency - The company has established a comprehensive operational system covering human resources, R&D, production, quality control, and project management[149]. - The company has implemented an ERP resource management system to enhance operational efficiency through real-time data updates and dynamic monitoring[149]. - The company has established a stable management team and a robust governance structure to support its rapid growth and operational scale[156]. - The company has implemented a stock incentive system to maintain talent stability and support strategic goals[147]. Customer Base and Sales - The company employs a direct sales and distribution model, establishing stable partnerships with renowned distributors such as Thermo Fisher and Sigma-Aldrich, and actively expanding its global market presence[77]. - The company has a diverse customer base, including multinational pharmaceutical giants like Pfizer and Roche, as well as prestigious research institutions such as Harvard University and Oxford University[72]. - The top five customers contributed ¥23,275.85 million, accounting for 17.14% of total annual sales, with no related party sales included[180]. Inventory and Assets - The inventory balance increased, which is necessary to support future revenue growth, but it also impacted current accounting profits due to inventory impairment provisions[160]. - The company’s goodwill rose by 1,956.55% to ¥301,182,973.14, primarily due to the acquisition of pharmaceutical assets[193]. - The company’s fixed assets increased by 170.90% to ¥623,149,212.42, due to the completion of production facilities[193]. - Accounts receivable increased by 133.83% to ¥336,860,225.55, representing 9.36% of total assets, due to business expansion[191]. - Inventory surged by 158.72% to ¥910,876,848.98, making up 25.32% of total assets, driven by increased orders from downstream customers[192].

（2022 年 4 月） 上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------|------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | 其他（电话会议、论坛） | | 参与单位名称 | 2022 年 4 月 25 日 | | | | 信达证券、嘉实基金 | | | | 2022 年 4 月 28 日 | | | | 兴业证券、平安养老、开源证券、广发基金 | | | | 2022 年 4 月 29 日 | | | | | 天风证券、新华基金、信达证券、上投摩根、开源证券、富国基金 | | 时间 | 2022 年 4 月 25 日、 2 ...

（2022 年 6 月） 上海皓元医药股份有限公司 上海市浦东新区张衡路1999 号 3号楼 201203 上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------------|--------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | 其他（电话会议、论坛） | | 参与单位名称 | 2022 年 6 月 9 日 | | | | 长江证券、汇添富基金 | | | | 2022 年 6 月 10 日 | | | | 开源证券、工银瑞信基金 | | | | 2022 年 6 月 13 日 | | | | 开源证券、华商基金 | | | | ...

（2022 年 5 月） 上海皓元医药股份有限公司 上海市浦东新区张衡路 1999 号 3 号楼 201203 上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------|------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | 其他（电话会议、论坛） | | 参与单位名称 | 2022 年 5 月 5 日 | | | | 开源证券、南方基金、西部证券、宝盈基金 | | | | 2022 年 5 月 6 日 | | | | 兴业证券、融通基金、平安资管 | | | | 2022 年 5 月 7 日 | | | | 开源证券、华安基金、农银汇理 ...

Financial Performance - The company's revenue for Q3 2022 was ¥348,854,594.13, representing a 44.77% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥41,466,989.23, a decrease of 15.34% compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥32,040,541.26, down 31.07% year-over-year[6]. - For the first three quarters of 2022, the company achieved total revenue of 970 million RMB, a year-on-year increase of 39.38%[20]. - The net profit attributable to shareholders for the same period was 158 million RMB, representing a year-on-year growth of 9.63%, and a 25.49% increase when excluding the impact of equity incentives[20]. - In Q3 2022, the company reported revenue of 349 million RMB and a net profit of 41.47 million RMB, with a 3.30% year-on-year growth in net profit after excluding equity incentives[20]. - The company reported a net profit margin improvement, with net profit for the first three quarters of 2022 showing a significant increase compared to the previous year[41]. - The net profit for the current period is CNY 155,926,398.04, an increase from CNY 143,926,979.85 in the previous period, representing a growth of approximately 8.8%[44]. - The total profit for the current period is CNY 168,455,421.98, slightly down from CNY 169,934,416.48 in the previous period[44]. - The operating profit stands at CNY 167,437,231.19, compared to CNY 170,205,778.88 in the previous period, indicating a decrease of about 1.5%[44]. - The company reported a total comprehensive income of CNY 161,633,635.24, up from CNY 143,772,651.48 in the previous period, reflecting an increase of approximately 12.4%[46]. Research and Development - R&D investment for Q3 2022 totaled ¥58,835,045.62, an increase of 128.06% compared to the same period last year[10]. - R&D investment accounted for 16.87% of revenue in Q3 2022, up 6.16 percentage points year-over-year[10]. - The company attributed the decrease in net profit to increased R&D spending and expansion of personnel to enhance operational capabilities[18]. - The company is actively expanding its R&D capabilities and production capacity to meet growing business demands, with significant investments in various research centers and production facilities[20]. - The company continues to focus on innovation and R&D as core drivers of growth, enhancing its operational capabilities across multiple locations[20]. - Research and development expenses increased significantly to CNY 141,552,468.37 in 2022 from CNY 68,923,395.62 in 2021, reflecting a growth of approximately 105.5%[41]. Assets and Liabilities - The company's total assets as of the end of Q3 2022 were ¥2,791,332,605.55, reflecting a 17.06% increase from the end of the previous year[10]. - The total assets of the company reached 2.791 billion RMB, up 17.06% from the end of the previous year, while the net assets attributable to shareholders increased by 8.39% to 1.975 billion RMB[20]. - Total liabilities increased to CNY 803,856,587.34 from CNY 548,110,908.44, representing a growth of approximately 46.5%[39]. - The company's equity attributable to shareholders rose to CNY 1,975,265,767.03, up from CNY 1,822,307,191.98, indicating an increase of about 8.4%[39]. - Cash and cash equivalents increased to CNY 1,617,861,693.43 from CNY 1,590,489,175.71, showing a growth of approximately 1.7%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥148,541,803.99, a decrease of 819.69% compared to the previous year[10]. - Cash flow from operating activities generated a net outflow of CNY -148,541,803.99, contrasting with a net inflow of CNY 20,639,578.34 in the previous period[52]. - Cash inflow from investment activities totaled CNY 2,362,178,677.98, significantly higher than CNY 277,744.00 in the previous period[52]. - The company incurred cash outflows from investment activities amounting to CNY 2,909,029,781.05, compared to CNY 117,299,204.62 in the previous period[52]. - The net cash flow from financing activities was CNY 129,014,429.99, a decrease from CNY 1,048,560,115.42 in the previous period[54]. - The cash and cash equivalents at the end of the period were CNY 482,621,162.96, down from CNY 1,230,868,931.51 in the previous period[54]. Employee Growth - As of the end of the reporting period, the company had 2,785 employees, an increase of 1,299 employees compared to the end of the previous year, primarily in technical roles[20]. Strategic Focus - The company is deepening its participation in domestic and international market competition through a globalized and brand-focused development strategy[20]. - The company plans to expand its market presence and invest in new product development to drive future growth[41]. - The company has increased its short-term borrowings to CNY 101,573,233.87 from CNY 6,000,000.00, indicating a strategic move to leverage financing for growth initiatives[37].

Financial Performance - The company reported a semi-annual revenue of 500 million RMB, representing a 20% increase compared to the same period last year[3]. - The company's revenue for the first half of 2022 was ¥621,311,676.21, representing a 36.52% increase compared to ¥455,109,051.61 in the same period last year[31]. - The net profit attributable to shareholders for the same period was ¥116,382,646.40, up 22.51% from ¥95,000,151.55 in the previous year[31]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥109,913,214.65, reflecting a 17.40% increase from ¥93,625,063.12 year-on-year[31]. - The gross profit margin improved to 45%, up from 40% in the previous year, indicating better cost management[3]. - The company achieved operating revenue of 621.31 million yuan, a year-on-year increase of 36.52%[142]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 109.91 million yuan, up 17.40% compared to the previous year[142]. - Total assets grew by 10.10% to CNY 2,625,440,145.07 year-on-year[33]. - The net assets attributable to shareholders increased by 5.11% to CNY 1,915,512,928.56 compared to the previous year[33]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users[3]. - The company expects a revenue growth forecast of 25% for the next half of the year, driven by new product launches and market expansion[3]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of the fiscal year[3]. - The company has a global customer base, with significant outreach in North America, Europe, Japan, South Korea, and India[52]. Research and Development - Investment in R&D increased by 30%, focusing on the development of new small molecule drugs and innovative technologies[3]. - The proportion of R&D investment to operating revenue rose by 3.83 percentage points to 13.31%[33]. - Research and development expenses increased by 91.81% year-on-year, totaling approximately ¥82.72 million, primarily due to the establishment of new R&D centers and an increase in R&D personnel and related costs[70]. - The company has developed over 16,000 proprietary products and has a reserve of more than 71,000 molecular building blocks and tool compounds[41]. - The company has developed over 100 types of active pharmaceutical ingredients (APIs) and intermediates, with 94 products ready for industrialization as of the reporting period[45]. - The company has established 30 ongoing research projects in key therapeutic areas, including oncology and diabetes treatment[127]. Acquisitions and Strategic Initiatives - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in drug development[3]. - The company is actively pursuing acquisitions, including the acquisition of Hefei Ouchuang Gene to enhance its capabilities in high-end molecular building blocks and CRO services[111]. - The company plans to acquire 100% equity of Yaoyuan Pharmaceutical to quickly enhance its formulation CDMO capabilities and expand GMP production capacity, with the acquisition already under review by the Shanghai Stock Exchange[130]. Operational Challenges and Risks - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[3]. - The company faces risks from potential declines in R&D investment in the pharmaceutical industry, which could impact client demand for its services[134]. - Increased competition in both domestic and international markets poses a risk to the company's market position and operational performance[136]. - The company is exposed to risks related to talent retention and management challenges due to rapid business expansion[140]. Environmental and Compliance - The company emphasizes environmental protection, with no pollution incidents or administrative penalties reported during the first half of 2022[174]. - The company has implemented a comprehensive environmental management system, including emergency response plans and regular monitoring of pollutants[188]. - The company achieved ISO 14001:2015 certification for its environmental management system, indicating a commitment to continuous improvement[188]. Future Outlook - The company expects new product launches to contribute an additional C million in revenue, with anticipated market expansion into D regions[200]. - Future guidance includes a focus on sustainability practices, aiming to reduce carbon footprint by G% by 2025[200]. - The management emphasized the importance of maintaining compliance with regulatory commitments, ensuring transparency in all transactions[200].

Financial Performance - The company's operating revenue for Q1 2022 was ¥299,992,261.46, representing a year-on-year increase of 33.02%[6] - The net profit attributable to shareholders was ¥62,338,825.02, reflecting a growth of 15.06% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥58,802,674.97, which is an increase of 9.97% year-on-year[6] - Total operating revenue for Q1 2022 was CNY 299,992,261.46, an increase of 33.0% compared to CNY 225,516,899.25 in Q1 2021[25] - Net profit for Q1 2022 reached CNY 61,771,891.90, representing a 14.5% increase from CNY 54,178,609.59 in Q1 2021[29] - The company reported a total comprehensive income of CNY 61,596,230.95 for Q1 2022, compared to CNY 54,492,549.93 in Q1 2021[31] Research and Development - The total R&D investment amounted to ¥33,470,762.57, marking an increase of 84.54% compared to the previous year[9] - R&D expenses accounted for 11.16% of operating revenue, up by 3.12 percentage points year-on-year[9] - R&D expenses in Q1 2022 amounted to CNY 33,470,762.57, a significant increase of 84.5% compared to CNY 18,137,381.68 in Q1 2021[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,500,557,699.50, an increase of 4.86% from the end of the previous year[9] - The equity attributable to shareholders was ¥1,880,280,351.08, reflecting a growth of 3.18% compared to the end of the previous year[9] - The total liabilities increased to CNY 606,710,792.77 in the latest report, up from CNY 548,110,908.44[24] - The company's total assets amounted to approximately CNY 2.50 billion, an increase from CNY 2.38 billion as of December 31, 2021, representing a growth of about 4.9%[19] Cash Flow - The net cash flow from operating activities was negative at -¥3,784,513.39, a decline of 107.29% year-on-year[6] - In Q1 2022, the cash inflow from operating activities was $258,607,901.28, an increase of 14.7% compared to $225,494,489.85 in Q1 2021[36] - The net cash flow from operating activities in Q1 2022 was -$3,784,513.39, a significant decline from $51,880,978.55 in Q1 2021[36] - Cash outflow from investing activities totaled $323,541,199.87 in Q1 2022, compared to $47,300,739.74 in Q1 2021, indicating a substantial increase in investment expenditures[37] - Cash inflow from financing activities was $112,400,000.00 in Q1 2022, with a net cash flow of $100,907,907.55, a recovery from -$15,393,935.25 in Q1 2021[37] Current and Non-Current Assets - The company's cash and cash equivalents decreased to approximately CNY 858.29 million from CNY 1.04 billion, a decline of about 17.3%[19] - Accounts receivable increased significantly to approximately CNY 211.46 million, up from CNY 144.06 million, reflecting a growth of approximately 46.8%[19] - Inventory levels rose to approximately CNY 424.63 million, compared to CNY 352.07 million, indicating an increase of about 20.6%[19] - The company's total current assets amounted to approximately CNY 1.58 billion, slightly down from CNY 1.59 billion, a decrease of about 0.3%[19] - The company’s total non-current assets increased to approximately CNY 921.59 million from CNY 794.06 million, representing a growth of about 16.0%[22] Equity and Earnings - Basic earnings per share for Q1 2022 were CNY 0.84, down from CNY 0.97 in Q1 2021[31] - The total equity attributable to shareholders of the parent company rose to CNY 1,880,280,351.08, compared to CNY 1,822,307,191.98 in the previous period[24] - Deferred income increased to CNY 61,863,956.34 from CNY 59,969,218.96, indicating a growth of 3.2%[24]

Financial Performance - The company's operating revenue for 2021 was approximately ¥969.23 million, representing a 52.61% increase compared to ¥635.10 million in 2020[33]. - The net profit attributable to shareholders for 2021 was approximately ¥190.98 million, up 48.70% from ¥128.43 million in 2020[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥177.24 million, reflecting a 49.41% increase from ¥118.62 million in 2020[33]. - The company's total assets at the end of 2021 were approximately ¥2.38 billion, a 178.29% increase from ¥856.84 million at the end of 2020[33]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.82 billion, showing a significant increase of 245.26% from ¥527.81 million at the end of 2020[33]. - The net cash flow from operating activities for 2021 was approximately ¥57.83 million, a decrease of 50.48% compared to ¥116.79 million in 2020[33]. - The basic earnings per share for the year was 2.94 yuan, an increase of 27.83% from the previous year[36]. - The company achieved a total operating revenue of RMB 962,064,584.03, representing a year-on-year growth of 52.50%[153]. - The revenue from the molecular blocks and tool compounds business reached RMB 544,977,157.21, an increase of 57.59% compared to the previous year[153]. - The revenue from the raw materials and intermediates business was RMB 417,087,426.82, reflecting a growth of 46.32% year-on-year[153]. Dividend and Share Capital - The company plans to distribute a cash dividend of 5.30 CNY per 10 shares, totaling approximately 39.4 million CNY, which represents 20.63% of the net profit attributable to shareholders for the year[8]. - The company intends to increase its total share capital from 74,342,007 shares to 104,078,809 shares by issuing 4 additional shares for every 10 shares held, resulting in a total of approximately 29.7 million new shares[8]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of its financial statements[8]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance and oversight[8]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, indicating financial integrity[13]. - The company has not violated decision-making procedures for external guarantees, further demonstrating compliance with regulations[13]. - The company has confirmed that there are no special arrangements in corporate governance that could affect the integrity of the annual report[10]. - The company has outlined various risks in its operations and has provided measures to mitigate these risks, emphasizing the importance of investor awareness[7]. Research and Development - The company is focused on expanding its research and development capabilities, particularly in innovative drug development and contract research services[24]. - The company aims to enhance its market presence through strategic partnerships and collaborations in the pharmaceutical industry[24]. - The company is committed to maintaining compliance with cGMP standards to ensure high-quality manufacturing processes[24]. - The R&D investment as a percentage of operating revenue was 10.67%, up by 0.47 percentage points from the previous year[36]. - The company is focusing on enhancing its research and development capabilities and expanding its product lines in the CRO and CDMO sectors[36]. - The company has developed over 58,600 types of molecular building blocks and tool compounds, with over 163,000 orders for molecular building blocks and over 116,000 orders for tool compounds during the reporting period[54]. - The company has completed the development of over 100 types of active pharmaceutical ingredients (APIs) and intermediates, with 92 products ready for industrialization, and has undertaken 192 projects in the generic drug business[54]. - The company has developed six core technology platforms, including high-potency active pharmaceutical ingredients (HPAPI) and multi-chirality complex drug technology, enhancing its R&D capabilities and industry competitiveness[89]. Market and Industry Trends - The pharmaceutical industry is expected to grow at a compound annual growth rate (CAGR) of 3% to 6%, reaching approximately $1.6 trillion by 2025, driven by increasing medical demands in an aging society[78]. - The domestic CDMO industry size increased from RMB 10.5 billion in 2016 to RMB 31.7 billion in 2020, with a compound annual growth rate (CAGR) of 32.0%[84]. - The domestic CDMO industry is projected to grow from RMB 31.7 billion in 2020 to RMB 123.5 billion by 2025, with a CAGR of 31.3%[84]. - The number of innovative drugs approved in China reached 30 in 2021, including 24 chemical drugs and 6 biological drugs, with 17 being anti-tumor drugs[81]. - The global pipeline of new drugs reached 18,582 in 2021, reflecting a 4.76% increase from 2020, indicating a healthy trend in early drug discovery and development[81]. Strategic Initiatives - The company is developing a one-stop compound synthesis route prediction and recommendation platform using AI technology to accelerate drug development[51]. - The company has established a unique business model that combines customer demand orientation with independent development, enhancing customer loyalty and satisfaction[77]. - The company plans to gradually transfer some production projects to its Ma'anshan industrialization base, forming a dual industrialization model of "self-production + outsourcing"[74]. - The company aims to enhance its innovation-driven R&D capabilities and build competitive barriers through core technology platforms[200]. - The strategic goal is to create an integrated, full-industry chain business model that provides comprehensive drug research and development services, aiming to become a world-class pharmaceutical R&D and production service enterprise[200]. Operational Challenges - The company faces risks related to rising labor costs and talent retention, which are critical for maintaining core competitiveness[140]. - Increased competition in domestic and international markets poses a risk to the company's operational performance[140]. - The company is expanding its operational scale, which may lead to management challenges if governance does not keep pace with growth[140]. - Environmental protection and safety production risks may increase due to the scale of production and stricter regulations[140].